Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
16.91
+3.38 (24.98%)
At close: Aug 13, 2025, 4:00 PM
16.57
-0.34 (-2.01%)
Pre-market: Aug 14, 2025, 9:00 AM EDT
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $13.82M in the quarter ending June 30, 2025, with 186.01% growth. This brings the company's revenue in the last twelve months to $199.89M, up 1,218.82% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$199.89M
Revenue Growth
+1,218.82%
P/S Ratio
4.86
Revenue / Employee
$1,561,664
Employees
128
Market Cap
923.23M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
STOK News
- 1 day ago - Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 3 days ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 7 days ago - Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - Business Wire
- 7 days ago - Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 4 weeks ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - GlobeNewsWire
- 5 weeks ago - Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Business Wire
- 2 months ago - Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha